{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-011637","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.996315+00:00","generated_at":"2026-06-10T23:09:46.267806+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palatin completes enrollment in Phase 3 dry eye study (PL9643); 570 patients enrolled, topline expected Q4 2023","bullets":["PL9643 MELODY-1 Phase 3 study enrolled 570 patients with moderate-to-severe dry eye disease.","Topline data anticipated by end of Q4 2023; interim analysis of first 120 patients showed safety and efficacy.","Assuming positive results, NDA submission to FDA expected mid-2025 after two more Phase 3 studies in 2024-2025.","Company highlighted PL9643's novel mechanism of action and differentiated profile vs. current DED treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-011637","json":"https://secwatch.observer/filing/0001654954-23-011637.json","markdown":"https://secwatch.observer/filing/0001654954-23-011637.md","text":"https://secwatch.observer/filing/0001654954-23-011637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423011637/0001654954-23-011637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423011637/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:09:46.267806+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}